Logo

Lilly Reports Results of Tirzepatide in P-lll SURPASS-3 and 5 Trials for Type-2 Diabetes

Share this

Lilly Reports Results of Tirzepatide in P-lll SURPASS-3 and 5 Trials for Type-2 Diabetes

Shots:

  • The P-lll SURPASS-3 study involves assessing Tirzepatide (5/10/15 mg) vs titrated insulin degludec in 1444 participants in a ratio (1:1:1:1) with T2D treated with metformin with or without an SGLT-2 inhibitor for 52wks.
  • The P-lll SURPASS-5 study involves assessing Tirzepatide (5/10/15 mg) vs PBO in 475 participants in a ratio (1:1:1:1) in adults with inadequately controlled T2D already being treated with insulin glargine with or without metformin
  • The SURPASS-3 & 5 shows A1C reduction: (-1.93% /-2.20%/-2.37% vs- 1.34%) & (-2.23%/-2.59%/ -2.59% vs -0.93%); Weight reduction: (-8.1%/ -11.4%/-13.9% vs +2.7%) & (-6.6%/-8.9%/-11.6% vs +1.7%) respectively

 ­ Ref: PRNewswire | Image: Fortune

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions